Added Value of 3- Versus 2-Dimensional Echocardiography Left Ventricular Ejection Fraction to Predict Arrhythmic Risk in Patients With Left Ventricular Dysfunction.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
10 2019
Historique:
received: 20 02 2018
revised: 27 06 2018
accepted: 19 07 2018
pubmed: 17 9 2018
medline: 26 5 2020
entrez: 17 9 2018
Statut: ppublish

Résumé

This study sought to evaluate the potential clinical impact of using 3-dimensional echocardiography (3DE) to measure left ventricular ejection fraction (LVEF) in patients considered for implantable cardioverter-defibrillator (ICD) implantation and to assess the predictive value of 3DE LVEF for arrhythmic events. ICD therapy is currently recommended to prevent sudden cardiac death in patients with symptomatic heart failure and LVEF ≤35%, and in asymptomatic patients with ischemic heart disease and LVEF ≤30%. Two-dimensional echocardiography (2DE) is currently used to calculate LVEF. However, 3DE has been reported to be more reproducible and accurate than 2DE to measure LVEF. The study prospectively enrolled 172 patients with LV dysfunction (71% ischemic). Both 2DE and 3DE LVEF were obtained during the same study. The outcome was the occurrence of major arrhythmic events (sudden cardiac death, aborted cardiac arrest, appropriate ICD therapy). After a median follow up of 56 (range 18 to 65) months, major arrhythmic events occurred in 30% of the patients. Compared with 2DE, 3DE changed the assignment above or below the LVEF thresholds for ICD implantation in 20% of patients, most of them having 2DE LVEFs within ± 10% from threshold. By cause-specific hazard model, 3DE LVEF was the only independent predictor of the occurrence of major arrhythmic events. LVEF by 3DE was an independent predictor of major arrhythmic events and improved arrhythmic risk prediction in patients with LV dysfunction. When compared with 2DE LVEF, 3DE measurement of LVEF may change the decision to implant an ICD in a sizable number of patients.

Sections du résumé

OBJECTIVES
This study sought to evaluate the potential clinical impact of using 3-dimensional echocardiography (3DE) to measure left ventricular ejection fraction (LVEF) in patients considered for implantable cardioverter-defibrillator (ICD) implantation and to assess the predictive value of 3DE LVEF for arrhythmic events.
BACKGROUND
ICD therapy is currently recommended to prevent sudden cardiac death in patients with symptomatic heart failure and LVEF ≤35%, and in asymptomatic patients with ischemic heart disease and LVEF ≤30%. Two-dimensional echocardiography (2DE) is currently used to calculate LVEF. However, 3DE has been reported to be more reproducible and accurate than 2DE to measure LVEF.
METHODS
The study prospectively enrolled 172 patients with LV dysfunction (71% ischemic). Both 2DE and 3DE LVEF were obtained during the same study. The outcome was the occurrence of major arrhythmic events (sudden cardiac death, aborted cardiac arrest, appropriate ICD therapy).
RESULTS
After a median follow up of 56 (range 18 to 65) months, major arrhythmic events occurred in 30% of the patients. Compared with 2DE, 3DE changed the assignment above or below the LVEF thresholds for ICD implantation in 20% of patients, most of them having 2DE LVEFs within ± 10% from threshold. By cause-specific hazard model, 3DE LVEF was the only independent predictor of the occurrence of major arrhythmic events.
CONCLUSIONS
LVEF by 3DE was an independent predictor of major arrhythmic events and improved arrhythmic risk prediction in patients with LV dysfunction. When compared with 2DE LVEF, 3DE measurement of LVEF may change the decision to implant an ICD in a sizable number of patients.

Identifiants

pubmed: 30219408
pii: S1936-878X(18)30659-4
doi: 10.1016/j.jcmg.2018.07.011
pii:
doi:

Types de publication

Comparative Study Journal Article Observational Study Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

1917-1926

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Hugo Rodríguez-Zanella (H)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy; National Institute of Cardiology of Mexico, Ignacio Chávez, México City, Mexico.

Denisa Muraru (D)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy. Electronic address: denisa.muraru@gmail.com.

Eleonora Secco (E)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Francesca Boccalini (F)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Danila Azzolina (D)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Patrizia Aruta (P)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Elena Surkova (E)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy; Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, England.

Davide Genovese (D)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Giacomo Cavalli (G)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Giuseppe Sammarco (G)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Niccolò Ruozi (N)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Rosaria M Tenaglia (RM)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Oscar Calvillo-Argüelles (O)

National Institute of Cardiology of Mexico, Ignacio Chávez, México City, Mexico.

Chiara Palermo (C)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Sabino Iliceto (S)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Luigi P Badano (LP)

Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH